Clinical review of antidiabetic drugs: Implications for type 2 diabetes mellitus management

Frontiers in Endocrinology

Volumn 8, Issue JAN, 2017, Pages

  Chaudhury, Arun ^a   Duvoor, Chitharanjan ^a,b   Reddy Dendi, Vijaya Sena ^c   Kraleti, Shashank ^b   Chada, Aditya ^a,b   Ravilla, Rahul ^a,b   Marco, Asween ^a,d   Shekhawat, Nawal Singh ^a,e   Montales, Maria Theresa ^b   Kuriakose, Kevin ^f   Sasapu, Appalanaidu ^b   Beebe, Alexandria ^g   Patil, Naveen ^g   Musham, Chaitanya K ^h   Lohani, Govinda Prasad ⁱ   Mirza, Wasique ^j  

^a GIM Foundation   (United States)

^b UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^c Trinity Mother Frances Hospitals and Clinics   (United States)

^d UNIVERSITY OF ARKANSAS AT LITTLE ROCK   (United States)

^e Tutwiler Clinic   (United States)

^f VANDERBILT UNIVERSITY   (United States)

^g ARKANSAS DEPARTMENT OF HEALTH   (United States)

^h St Vincent Infirmary Medical Center   (United States)

ⁱ Baptist Hospital SpringHill   (United States)

^j Wright Center for Graduate Medical Education   (United States)

more..

Author keywords

Chronic; Clinical management; Diabetes; Insulin; Primary care

Indexed keywords

ANTIDIABETIC AGENT; BIGUANIDE; EXENDIN 4; HEMOGLOBIN A1C; INCRETIN; INSULIN; LIRAGLUTIDE; MEGLITINIDE; METFORMIN; PIOGLITAZONE; ROSIGLITAZONE;

BLOOD GLUCOSE MONITORING; CLINICAL TRIAL (TOPIC); GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; INSULIN RESISTANCE; LIFESTYLE; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET BETA CELL; SECRETION (PROCESS); SHORT SURVEY;

EID: 85011846490     PISSN: None     EISSN: 16642392     Source Type: Journal    
DOI: 10.3389/fendo.2017.0006     Document Type: Short Survey

References (51)

1. Internal Clinical Guidelines Team. Type 2 Diabetes in Adults: Management. London: National Institute for Health and Care Excellence (2015). 28 p.
2. Standards of medical care in diabetes-2016: summary of revisions. Diabetes Care (2016) 39(Suppl 1):S4-5. doi:10.2337/dc16-S003.
3. American Diabetes Association. Standards of medical care in diabetes. Diabetes Care (2014) 37(1):514-80. doi:10.2337/dc14-S014.
4. Kalra S, Agrawal N. Diabetes and HIV: current understanding and future perspectives. Curr Diab Rep (2013) 13(3):419-27. doi:10.1007/s11892-013-0369-9.
5. Sukhija R, Prayaga S, Marashdeh M, Bursac Z, Kakar P, Bansal D, et al. Effect of statins on fasting plasma glucose in diabetic and nondiabetic patients. J Investig Med (2009) 57(3):495-9. doi:10.2310/JIM.0b013e318197ec8b.
6. Mancia G. Preventing new-onset diabetes in thiazide-treated patients. Lancet Diabetes Endocrinol (2016) 4(2):90-2. doi:10.1016/S2213-8587(15)00391-5.
7. Santos-Longhurst A, Krucik G. Type 2 Diabetes Statistics and Facts. Healthline (2014). Available from: www.healthline.com/health/type-2-diabetes/statistics.
8. Centers for Disease Control and Prevention. Diabetes Latest. (2014). Available from: www.cdc.gov/features/diabetesfactsheet.
9. American Diabetes Association. National Diabetes Statistics Report: Statistics about Diabetes. (2014). Available from: www.diabetes.org/diabetes-basics/statistics/.
10. American Diabetes Association. Fast Facts-Data and Statistics about Diabetes. DiabetesPro (2014). Available from: http://professional.diabetes.org/content/fast-facts-data-and-statistics-about-diabetes.
11. (2016). Available from: http://care.diabetesjournals.org/content/39/Supplement_1.
12. Nyenwe EA, Kitabchi AE. The evolution of diabetic ketoacidosis: an update of its etiology, pathogenesis and management. Metabolism (2016) 65(4):507-21. doi:10.1016/j.metabol.2015.12.007.
13. Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ (2000) 321:405-12. doi:10.1136/bmj.321.7258.405.
14. Stoppler M, Shiel W. Hemoglobin A1C Test. EMedicine health. (2016). Available from: http://www.emedicinehealth.com/hemoglobin_a1c_hba1c/article_em.htm.
15. Dansinger M. The Hemoglobin A1C Test for Diabetes. WebMD (2015). Available from: http://www.webmd.com/diabetes/guide/glycated-hemoglobin-test-hba1c.
16. For People of African, Mediterranean, or Southeast Asian Heritage: Important Information about Diabetes Blood Tests. National Institute of Diabetes and Digestive and Kidney Diseases (2011). Available from: http://www.niddk.nih.gov/health-information/health-topics/diagnostic-tests/people-african-mediterranean-southeast-asian-heritage-important-information-diabetes-blood-tests/Pages/index.aspx.
17. American Diabetes Association. Screening for Type 2 Diabetes. (Vol. 18). Clinical Diabetes (2000). Available from: http://journal.diabetes.org/clinicaldiabetes/v18n22000/pg69.htm.
18. Tabak A, Herder C, Rathmann W, Brunner E, Kivimaki M. Prediabetes: a high risk state for developing diabetes. Lancet (2012) 379(9833):2279-90. doi:10.1016/S0140-6736(12)60283-9.
19. Tuso P. Prediabetes and lifestyle modification: time to prevent a preventable disease. Perm J (2014) 18(3):88-93. doi:10.7812/TPP/14-002.
20. Consumption of Carbohydrate in People with Diabetes. Diabetes UK. (2011). Available from: https://www.diabetes.org.uk/Professionals/Position-statements-reports/Food-nutrition-lifestyle/Consumption-of-carbohydrate-in-people-with-diabetes/.
21. Riccardi G, Rivellese A. Effects of dietary fiber and carbohydrate on glucose and lipoprotein metabolism in diabetic patients. Diabetes Care (1991) 14(12):1115-25. doi:10.2337/diacare.14.12.1115.
22. Umpierre D, Ribeiro PA, Kramer CK, Leitão CB, Zucatti AT, Azevedo MJ, et al. Physical activity advice only or structured exercise training and association with HbA1c levels in type 2 diabetes: a systematic review and meta-analysis. JAMA (2011) 305(17):1790-9.
23. Pietraszek A, Gregersen S, Hermansen K. Alcohol and type 2 diabetes. A review. Nutr Metab Cardiovasc Dis (2010) 20(5):366-75. doi:10.1016/j.numecd.2010.05.001.
24. Defronzo RA. Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes (2009) 58(4):773-95. doi:10.2337/db09-9028.
25. Bailey CJ. The current drug treatment landscape for diabetes and perspectives for the future. Clin Pharmacol Ther (2015) 98(2):170-84. doi:10.1002/cpt.144.
26. James JC, Andrew SR, Charles FS Jr, Annie N. PA-C diagnosis and management of diabetes: synopsis of the 2016; American Diabetes Association standards of medical care in diabetes. Ann Intern Med (2016) 164:542-52. doi:10.7326/M15-3016.
27. Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R, et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care (2009) 32(1):193. doi:10.2337/dc08-9025.
28. Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care (2015) 38(1):140-9. doi:10.2337/dc14-2441.
29. Palmer SC, Mavridis D, Nicolucci A, Johnson DW, Tonelli M, Craig JC, et al. Comparison of clinical outcomes and adverse events associated with glucose-lowering drugs in patients with type 2 diabetes: a meta-analysis. JAMA (2016) 316(3):313-24. doi:10.1001/jama.2016.9400.
30. (2016). Available from: http://www.clevelandclinicmeded.com/medicalpubs/diseasemanagement/endocrinology/diabetes-mellitus-treatment/.
31. Viollet B, Guigas B, Garcia N, Leclerc J, Foretz M, Andreelli F. Cellular and molecular mechanisms of metfromin: an overview. Clin Sci (Lond) (2012) 122(6):253-70. doi:10.1042/CS20110386.
32. Inzucchi SE, Lipska KJ, Mayo H, Bailey CJ, McGuire DK. Metformin in patients with type 2 diabetes and kidney disease: a systematic review. JAMA (2014) 312(24):2668-75. doi:10.1001/jama.2014.15298.
33. Fogelman Y, Kitai E, Blumberg G, Golan-Cohen A, Rapoport M, Carmeli E. Vitamin B12 screening in metformin-treated diabetics in primary care: were elderly patients less likely to be tested? Aging Clin Exp Res (2016). doi:10.1007/s40520-016-0546-1.
34. Nathan DM, Buse JB, Kahn SE, Krause-Steinrauf H, Larkin ME, Staten M, et al. Rationale and design of the glycemia reduction approaches in diabetes: a comparativeeffectiveness study (GRADE). Diabetes Care (2013) 36(8):2254-61. doi:10.2337/dc13-0356.
35. Nauck MA, Meier JJ. The incretin effect in healthy individuals and those with type 2 diabetes: physiology, pathophysiology, and response to therapeutic interventions. Lancet Diabetes Endocrinol (2016) 4(6):525-36. doi:10.1016/S2213-8587(15)00482-9.
36. Maruthur NM, Tseng E, Hutfless S, Wilson LM, Suarez-Cuervo C, Berger Z, et al. Diabetes medications as monotherapy or metformin-based combination therapy for type 2 diabetes: a systematic review and meta-analysis. Ann Intern Med (2016) 164(11):740-51. doi:10.7326/M15-2650.
37. Harris KB, McCarty DJ. Efficacy and tolerability of glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes mellitus. Ther Adv Endocrinol Metab (2015) 6(1):3-18. doi:10.1177/2042018814558242.
38. Riser Taylor S, Harris KB. The clinical efficacy and safety of sodium glucose cotransporter-2 inhibitors in adults with type 2diabetes mellitus. Pharmacotherapy (2013) 33(9):984-99. doi:10.1002/phar.1303.
39. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet (1998) 352(9131):854-65; Erratum in: Lancet (1998) 352(9139):1558. doi:10.1016/S0140-6736(98)07037-8.
40. Siraj ES, Rubin DJ, Riddle MC, Miller ME, Hsu FC, Ismail-Beigi F, et al. Insulin dose and cardiovascular mortality in the ACCORD trial. Diabetes Care (2015) 38(11):2000-8. doi:10.2337/dc15-0598.
41. Ismail-Beigi F. Pathogenesis and glycemic management of type 2 diabetes mellitus: a physiological approach. Arch Iran Med (2012) 15(4):239-46.
42. Proks P, Reimann F, Green N, Gribble F, Ashcroft F. Sulfonylurea stimulation of insulin secretion. Diabetes (2002) 51(3):5368-76. doi:10.2337/diabetes.51.2007.S368.
43. Al-Arouj M, Bouguerra R, Buse J, Hafez S, Hassanein M, Ibrahim-Asharaf M, et al. Recommendations for management of diabetes during Ramadan. Diabetes Care (2005) 28:2305-11. doi:10.2337/diacare.28.9.2305.
44. Echouffo-Tcheugui JB, Dagogo-Jack S. Preventing diabetes mellitus in developing countries. Nat Rev Endocrinol (2012) 8(9):557-62; Erratum in: Nat Rev Endocrinol (2012) 8(11):692. doi:10.1038/nrendo.2012.46.
45. Ronacher K, Joosten SA, van Crevel R, Dockrell HM, Walzl G, Ottenhoff TH. Acquired immunodeficiencies and tuberculosis: focus on HIV/AIDS and diabetes mellitus. Immunol Rev (2015) 264(1):121-37. doi:10.1111/imr.12257.
46. Weyer C, Bogardus C, Mott DM, Pratley RE. The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus. J Clin Invest (1999) 104:787-94. doi:10.1172/JCI7231.
47. Garber AJ, Abrahamson MJ, Barzilay JI, Blonde L, Bloomgarden ZT, Bush MA, et al. Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm-2016 executive summary. Endocr Pract (2016) 22(1):84-113. doi:10.4158/EP151126.CS.
48. Ferrannini E, DeFronzo RA. Impact of glucose-lowering drugs on cardiovascular disease in type 2 diabetes. Eur Heart J (2015) 36(34):2288-96. doi:10.1093/eurheartj/ehv239.
49. Evers SS, Sandoval DA, Seeley RJ. The physiology and molecular underpinnings of the effects of bariatric surgery on obesity and diabetes. Annu Rev Physiol (2016).
50. Reilly SM, Chiang SH, Decker SJ, Chang L, Uhm M, Larsen MJ, et al. An inhibitor of the protein kinases TBK1 and IKK-e improves obesity-related metabolic dysfunctions in mice. Nat Med (2013) 19(3):313-21. doi:10.1038/nm.3082.
51. Koch L. Obesity: teaching an old drug new tricks-amlexanox targets inflammation to improve metabolic dysfunction. Nat Rev Endocrinol (2013) 9(4):185. doi:10.1038/nrendo.2013.42.